Navigation Links
A cost effective heart failure drug hits the market!

tient's lifespan beyond the 12-month trial period. Even under the most pessimistic assumption that, over time, the drug would no longer provide therapeutic benefits the model predicted that for 95 percent of patients, health care costs would still amount to less than what is considered to be a reasonable threshold for cost-effectiveness.

As another statement by Dr.Angus clarifies, "Using very conservative restrictions, our model suggests that this drug, even if used for lifetime courses over many years, should be very cost-effective. The key will be appropriate patient selection and careful attention to compliance with treatment. Our findings apply to the types of individuals, African-Americans with moderate to severe heart failure, who were enrolled in AHeFT. We do not know whether similar benefits would be found in other groups of patients."

"Because we relied on the actual data regarding health care resource use, our primary findings are likely to be very robust, as robust as the overall clinical trial results from AHeFT," said Dr. Angus.

A-HeFT involved 1,050 African-American patients at 11 sites with New York Heart Association Class III or Class IV failure, which is defined as moderate to severe heart failure resulting in significant limitations to physical activity. AHeFT participants were randomly assigned to receive ISDN/HYD or a placebo in addition to their regular heart failure therapy. The patients' age averaged 56.8 years, and 40 percent of the patients were women. The patients were followed for an average of 12.8 months, and the study ended prematurely when a preliminary analysis showed that patients treated with ISDN/HYD had a significantly lower mortality 6.2 percent compared to 10.2 percent.

This study was aimed at the African –American community only.
'"/>




Page: 1 2

Related medicine news :

1. Morning after pill effective up to five days after having unprotected sex
2. Distraction therapy found very effective in postoperative patients
3. TELITHROMYCIN - the proven effective new drug for cap
4. Digital mammography proves effective
5. Treatment for pre-menstrual syndrome is ineffective
6. Cost-effective antibiotics for sinusitis treatment
7. An effective way to treat angina
8. Fluoride proves effective against fractures
9. Meningitis C vaccine a cost-effective success
10. An effective drug for lung cancer
11. Naltrexone effective for drinking problems
Post Your Comments:
(Date:9/8/2008)...aser scalpels, arthroscopic,surgery, genomic resea...rinary medicine is quickly expanding into new high...e benefit; it,s improving medicine for,people, too... care for their pets to,treat diseases like diabet... according to the American Veterinary Medical Asso...
(Date:9/8/2008)...zine examines Iraq and Afghanistan veterans, strug..., Washington, DC (PRWEB) S...by veterans of the Iraq and Afghanistan wars about... addiction disorders are featured in the current i...ublication of the National Council for Community B...
(Date:9/7/2008)...f older patients successfully treated for colorect...le to detect any recurrence of cancer. The study, ... , a peer-reviewed journal of the American Cancer ...monitoring of colorectal cancer survivors could af...y curative surgery for colorectal cancer have an i...
(Date:9/7/2008)... appear to lower a man,s PSA level, the blood biom...her a man is at risk of prostate cancer. , But t.... 8 in the journal Cancer , caution that men shou... prostate cancer just yet. , "We showed that me...rin and other non-steroidal anti-inflammatory drug...
Breaking Medicine News(10 mins):Health News:High-Tech Vet Medicine Saving Lives of Pets and People 2Health News:Helping Veterans in Our Communities 2Health News:Helping Veterans in Our Communities 3Health News:Many colorectal cancer survivors do not receive recommended follow-up care 2Health News:Common painkillers lower levels of prostate cancer biomarker 2
...habits being replaced by Western lifestyles and di...ral indigenous populations across Asia, the Pacif...s. Professor Martin Silink, head of the Brussels-... said that indigenous people appeared to have a gr...
...jectable anti-TNF therapy that has FDA approval fo...ven effective in children with juvenile rheumatoid... week at the American College of Rheumatology Annu...DC. The immunosuppressant adalimumab, currently u...
...udy conducted by cardiologists of Duke University ...an be used as a conventional method for detecting ...system disorder sarcoidosis, who are at higher ris...ng MRI to discover minute areas of heart damage be...
...rom dengue so far, Ranchi registered its first dea...ngh, a public relations officer of the Central Min...ndia Ltd (CIL) undertaking, died of dengue Sunday ...he Guru Nanak Hospital here Saturday. The doctor...
Other Medicine News:Health News:Diabetes- a Threat to Several Indigenous Populations 2Health News:Adalimumab Proves Effective for Children with Juvenile Rheumatoid Arthritis 2Health News:MRI Detects Early Heart Damages In Patients 2Health News:MRI Detects Early Heart Damages In Patients 3
(Date:9/3/2008)...G, China, Sept. 3 /- Simcer...nufacturer and supplier of,branded generic pharmac...cer biotech product Endu (also known as Endostar) ...ase IV clinical study., At the request of the SFD...further validate the safety and therapeutic effica...
(Date:9/3/2008)... term follow up results from chronically infected ...ositive data obtained earlier in 2008, - Study i...d long-term antiviral effect of therapeutic...d strongly support move into a second generation, ...(R) acting through TLR ...
(Date:9/3/2008)...LS, Belgium and GENEVA, Sept. 3 /- Ar...stone in CHO based monoclonal antibody,production ...er 31 grams,per liter. This record level was accom...gies: (1) a high-performance stable Selexis CHO,pr...eading scientists at,Selexis SA using their propri...
(Date:9/3/2008)...lysis showed that Multaq(R) (dronedarone) decrease... fibrillation or atrial flutter already ...BRIDGEWATER, N.J., Sept. 3 /PRNewswire-FirstCall/ ...from the ATHENA study were presented today at,the ...ety of Cardiology,congress 2008, in Munich, German...
Breaking Medicine Technology:Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 2Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Survey Reveals Most Americans Planning Vacations Within the U S 3B Tummy Troubles Top Travel Health Woes 19424 1Survey Reveals Most Americans Planning Vacations Within the U S 3B Tummy Troubles Top Travel Health Woes 19424 2Survey Reveals Most Americans Planning Vacations Within the U S 3B Tummy Troubles Top Travel Health Woes 19424 3Debiopharm Signs License Agreement for Marketing of Salvacyl 28R 29 Moapar 28R 29 3 Month in Treatment of Sexual Deviations 5420 1Debiopharm Signs License Agreement for Marketing of Salvacyl 28R 29 Moapar 28R 29 3 Month in Treatment of Sexual Deviations 5420 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention Deficit Hyperactivity Disorder 28ADHD 29 2070 1Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention Deficit Hyperactivity Disorder 28ADHD 29 2070 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention Deficit Hyperactivity Disorder 28ADHD 29 2070 3Genes may play role in risk assessment for prostate cancer among Hispanics and caucasians 3319 1Genes may play role in risk assessment for prostate cancer among Hispanics and caucasians 3319 2
...GE, Mass.--(BUSINESS WIRE)--Jun 6, 2007 - Combinat...that data from its,randomized, blinded, placebo-co...ients with osteoarthritis (OA) and rheumatoid,arth... against,Rheumatism (EULAR) Annual Congress of Rhe...Spain., Schedule of Events: , -- Satellite Symposi...
...33 reduces esophageal reflux - , Waltham, Mass., J...reported positive results of its randomized, doubl...33 for gastroesophageal,reflux disease (GERD). Th...pt for DDP733 as a treatment for nocturnal GERD,(N...tical,significance over placebo on the primary end...
Other Medicine Technology:Novel Mechanism Insights and Additional Data on CombinatoRx Drug,Candidates to Be Presented at Upcoming EULAR Meeting 2Novel Mechanism Insights and Additional Data on CombinatoRx Drug,Candidates to Be Presented at Upcoming EULAR Meeting 3Dynogen's DDP733 Reduces Reflux in Phase 1b GERD Study 2Dynogen's DDP733 Reduces Reflux in Phase 1b GERD Study 3
The Explorer 360 and 360 Jr. catheters have a rotational connector for ease of use during procedures.
...of the PARAHISIAN catheter, combines an octapolar ...es, which permits the use of only one catheter for...is bundle electrograms. The "two catheters in one"...single venipuncture. The disadvantages of using tw...
Torqr Quadripolar Braided Shaft Fixed Curve. The Medtronic CardioRhythm Torqr Catheter is intended for use in diagnostic electrophysiologic procedures. The catheter is designed for recording intrac
Xtrem Dynamic is a line of steerable diagnosis catheters with micro handle. These catheters have been designed to provide pacing and recording during invasive electrophysiology procedures.
Medicine Products: